|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 11.29 Billion
|
|
Market Size (2030)
|
USD 17.20 Billion
|
|
CAGR (2025-2030)
|
7.24%
|
|
Fastest Growing Segment
|
Clinical Diagnostics
|
|
Largest Market
|
North America
|
Market Overview
Global Ancillary Reagents Market was
valued at USD 11.29 Billion in 2024 and is expected to reach USD 17.20 Billion in
the forecast period with a CAGR of 7.24% through 2030. The Global Ancillary
Reagents Market is experiencing significant growth due to the increasing demand
for high-quality reagents in research, diagnostics, and biopharmaceutical
applications. Ancillary reagents play a crucial role in various laboratory processes,
including cell culture, molecular biology, and immunoassays, ensuring the
accuracy and reliability of experimental results. The market is benefiting from
the rapid advancements in life sciences, where high-performance reagents are
essential for drug discovery, personalized medicine, and disease diagnostics.
The expanding application of ancillary reagents in next-generation sequencing
(NGS), polymerase chain reaction (PCR), and chromatography techniques is also
contributing to market expansion, as laboratories seek solutions that improve
workflow efficiency and data reliability.
The market is driven by the rising
investments in biotechnology and pharmaceutical research, increasing prevalence
of chronic diseases requiring advanced diagnostics, and the growing adoption of
automation in laboratories. The demand for ancillary reagents is fueled by the
need for high-throughput screening and efficient sample processing in research
and clinical settings. The expansion of biopharmaceutical manufacturing,
particularly for monoclonal antibodies and cell and gene therapies, has also
created a strong demand for high-quality reagents that support upstream and
downstream processes. Innovations in reagent formulations, such as chemically
defined and serum-free media, have enhanced product stability and consistency,
further driving adoption in critical applications. Regulatory compliance and
stringent quality control requirements in clinical and research laboratories
are also influencing the demand for validated and standardized reagents that
meet global safety and efficacy standards.
The market is witnessing trends such as
increased focus on custom reagent development, integration of digital solutions
for reagent management, and the rising use of sustainable and eco-friendly
reagents to reduce environmental impact. Challenges such as the high costs of
premium reagents, complexities in reagent storage and transportation, and
strict regulatory requirements for reagent validation may pose hurdles to
market growth. However, opportunities exist in the form of expanding research
collaborations, growing interest in point-of-care diagnostics, and the
development of novel reagents tailored for emerging analytical techniques. The
increasing penetration of artificial intelligence and automation in laboratory
workflows is expected to further drive demand for reagents that enhance process
efficiency and data accuracy, positioning the ancillary reagents market for
continued expansion in the coming years.
Key Market Drivers
Expansion
of Clinical Research and Drug Development Activities
The expansion of clinical research and
drug development activities is significantly driving the growth of the Global
Ancillary Reagents Market. Pharmaceutical and biotechnology companies are
investing heavily in drug discovery, preclinical studies, and clinical trials
to develop novel therapeutics for various diseases. Ancillary reagents play a
crucial role in these processes, ensuring accurate and reliable results in
laboratory testing, cell culture, and molecular biology applications. As the
demand for targeted therapies rises, the need for high-quality reagents to
support biomarker research, immunoassays, and genomic studies has significantly
increased.
Regulatory agencies such as the FDA and
EMA are imposing stringent guidelines on drug development, requiring extensive
validation and quality control at every stage of research. This has led to a
growing demand for ancillary reagents that meet high standards of purity,
stability, and reproducibility. Contract research organizations (CROs) are also
expanding their services, offering specialized testing solutions that depend on
high-performance reagents to deliver reliable data. As pharmaceutical companies
accelerate clinical trials for biologics, biosimilars, and gene therapies, the
demand for reagents used in cell culture media, assay development, and
analytical testing continues to grow.
The increasing focus on translational
research and personalized medicine is also boosting the adoption of ancillary
reagents in clinical applications. Researchers are leveraging advanced
molecular and immunological techniques to develop targeted therapies, requiring
high-quality reagents to maintain data accuracy and reproducibility. Emerging
technologies such as high-throughput screening and next-generation sequencing
are further propelling the need for sophisticated reagents that enhance
workflow efficiency and experimental outcomes. The rapid expansion of global
clinical research initiatives is expected to sustain the demand for ancillary
reagents, making them an essential component in the advancement of modern drug
discovery and development.
According to the U.S. Food and Drug
Administration (FDA), there has been a significant increase in the number of
drug application submissions incorporating artificial intelligence (AI)
components over the past few years. These submissions span various phases of
the drug product lifecycle, including nonclinical, clinical, postmarketing, and
manufacturing stages. This trend underscores the growing integration of
advanced technologies in drug development processes, further driving the need
for specialized ancillary reagents.
In Europe, the pharmaceutical industry
has elevated clinical trial activities, with the Agencia Española de
Medicamentos y Productos Sanitarios (AEMPS) authorizing 930 studies in 2024,
marking a 10% increase from the previous year. This surge in research activities
highlights the expanding scope of drug development in the region, contributing
to the rising demand for ancillary reagents. These developments reflect a
broader global trend of intensified clinical research and drug development
efforts, underscoring the critical role of ancillary reagents in supporting
these initiatives.
Advancements
in Molecular Biology and Genetic Engineering
Advancements in molecular biology and genetic
engineering are significantly driving the demand for ancillary reagents in
research and clinical applications. The increasing adoption of techniques such
as polymerase chain reaction (PCR), next-generation sequencing (NGS), and gene
editing technologies like CRISPR has created a need for high-quality reagents
to ensure accurate and reproducible results. Researchers rely on these reagents
for sample preparation, amplification, and detection processes, as even minor
variations in reagent composition can impact experimental outcomes. The growing
focus on personalized medicine and targeted therapies has intensified the need
for precise molecular assays, further boosting the demand for specialized
ancillary reagents.
Pharmaceutical and biotechnology companies are
increasingly investing in genetic engineering for drug discovery and
biopharmaceutical production. The development of monoclonal antibodies,
recombinant proteins, and gene therapies depends on specialized reagents that
facilitate cell culture, protein expression, and purification processes.
High-throughput screening methods used in drug discovery require optimized
buffer solutions, enzyme formulations, and stabilizing agents to enhance assay
sensitivity and efficiency. The expansion of synthetic biology, where
scientists design and modify biological systems for industrial and medical
applications, has also led to increased demand for reagents that support gene
synthesis and metabolic pathway engineering.
Regulatory agencies emphasize stringent quality
control in molecular diagnostics and therapeutic development, prompting
manufacturers to develop highly purified and standardized reagents. As research
institutions and clinical laboratories adopt automated workflows to improve
efficiency and reduce variability, the need for compatible and high-performance
ancillary reagents continues to grow. With continuous advancements in molecular
biology techniques and genetic engineering applications, the ancillary reagents
market is expected to witness sustained growth, driven by the increasing
complexity and precision requirements of modern life sciences research and
biotechnology innovations.
Recent advancements in genome-editing strategies,
particularly the CRISPR-Cas systems, have been identified among prokaryotic
organisms and engineered for genome manipulation studies. Due to their
advantageous features, the CRISPR-Cas systems are already employed in several
biological and medical research fields as the most suitable technique for
genome engineering.
Next-generation sequencing (NGS) is a powerful tool
used in genomics research. NGS can sequence millions of DNA fragments at once,
providing detailed information about the structure of genomes, genetic
variations, gene activity, and changes in gene behavior. Recent advancements
have focused on faster and more accurate sequencing, reduced costs, and
improved data analysis.
The U.S. Department of Agriculture
(USDA) reports that since the first successful commercialization of a
biotechnology-derived crop in the 1990s, many new crop varieties have been
developed and made available to U.S. farmers and farmers worldwide. U.S. farmers
have rapidly adopted many of these new genetically engineered (GE) varieties,
so that in 2012, 88 percent of the corn, 94 percent of the cotton, and 93
percent of the soybeans planted in the U.S. were varieties produced through
genetic engineering. These developments underscore the rapid progress in
molecular biology and genetic engineering, highlighting the increasing reliance
on high-quality ancillary reagents to support these innovative applications.
Growth
in Biopharmaceutical and Vaccine Production
The expansion of biopharmaceutical and
vaccine production is a key driver for the Global Ancillary Reagents Market. In
2021, approximately 16 billion vaccine doses, valued at USD 141 billion, were
supplied globally, nearly tripling the 2019 volume of 5.8 billion doses and
significantly increasing from the 2019 market value of USD 38 billion.
This surge was primarily driven by COVID-19 vaccines, highlighting the capacity
for rapid scale-up in vaccine manufacturing.
The increasing demand for biologics,
including monoclonal antibodies, recombinant proteins, and cell and gene
therapies, has heightened the need for high-quality ancillary reagents
essential in various bioprocessing stages. These reagents are crucial for
maintaining cell culture conditions, facilitating purification processes, and
ensuring rigorous quality control, thereby guaranteeing the stability and
efficacy of biopharmaceutical products. As companies aim to scale up production
and enhance yields, the demand for specialized buffers, stabilizers, and growth
media has grown significantly.
Vaccine development has also seen
substantial progress, driven by heightened awareness of infectious diseases and
the necessity for rapid immunization strategies. The emergence of novel vaccine
platforms, such as mRNA and viral vector-based vaccines, has intensified the
requirement for highly purified reagents that enable consistent manufacturing
processes. Regulatory agencies impose stringent quality standards on vaccine
production, necessitating the use of validated and compliant ancillary
reagents. Companies are investing in advanced reagent formulations that enhance
process efficiency, reduce variability, and ensure high product integrity,
thereby accelerating vaccine production timelines.
Strategic collaborations between
biopharmaceutical firms and reagent manufacturers are fostering innovation in
ancillary reagent development. Companies are introducing reagent solutions
tailored to specific bioprocessing needs, improving scalability and reproducibility.
The increasing number of biopharmaceutical facilities, along with rising
investments in contract manufacturing organizations (CMOs), is further
amplifying the demand for ancillary reagents. With continued advancements in
biotechnology, the role of ancillary reagents in optimizing drug and vaccine
production will remain crucial, supporting the expansion of the
biopharmaceutical industry.
Download Free Sample Report
Key Market Challenges
Stringent
Regulatory Requirements and Compliance Challenges
Stringent regulatory requirements and compliance
challenges present a significant hurdle for the Global Ancillary Reagents
Market. Regulatory agencies such as the U.S. Food and Drug Administration
(FDA), the European Medicines Agency (EMA), and other national authorities
impose rigorous standards on the development, manufacturing, and quality
control of ancillary reagents. These regulations are designed to ensure the
safety, efficacy, and consistency of reagents used in clinical diagnostics,
biopharmaceutical production, and research applications. Meeting these
stringent requirements demands extensive documentation, validation studies, and
continuous monitoring, which increases the complexity and cost of product
development. Companies operating in the market must allocate substantial
resources to comply with evolving regulatory frameworks, leading to prolonged
approval timelines and delayed market entry for new products.
Frequent updates in global regulatory guidelines
create challenges for reagent manufacturers in maintaining compliance.
Variations in regulatory expectations across different regions further
complicate the process, requiring companies to customize their strategies to
meet specific country-level requirements. Small and medium-sized enterprises
(SMEs) often struggle with these complexities due to limited financial and
technical resources, making it difficult to compete with larger players.
Failure to meet stringent compliance standards can result in product recalls,
legal penalties, and reputational damage, significantly impacting business
operations.
The rising emphasis on Good Manufacturing Practices
(GMP), data integrity, and quality assurance in reagent production adds another
layer of complexity. Manufacturers must invest in state-of-the-art facilities,
robust quality management systems, and skilled personnel to ensure regulatory
adherence. Navigating these challenges requires continuous collaboration with
regulatory authorities, investment in compliance infrastructure, and proactive
adaptation to new industry standards. Companies that successfully address these
compliance challenges gain a competitive advantage by ensuring product
reliability and securing trust among healthcare providers, researchers, and
regulatory bodies.
Lack
of Standardization and Reproducibility Issues
Lack of standardization and reproducibility issues
present a significant challenge in the Global Ancillary Reagents Market,
affecting research outcomes, diagnostic accuracy, and pharmaceutical
development. Variability in reagent composition, manufacturing processes, and
storage conditions can lead to inconsistent results across different
laboratories and clinical settings. Even minor deviations in reagent quality
can impact experimental reproducibility, leading to discrepancies in research
findings or misinterpretations in diagnostic applications. The absence of
universally accepted standards complicates the validation of reagents across
multiple applications, making it difficult for researchers and clinicians to
ensure data reliability.
Reproducibility issues are particularly concerning in
fields such as molecular diagnostics, genomics, and drug discovery, where
precision and consistency are critical. Variability in reagent performance can
lead to false-positive or false-negative results, ultimately affecting patient
care and delaying therapeutic advancements. Many laboratories rely on reagents
from multiple suppliers, each with slight formulation differences, further
complicating standardization efforts. Regulatory agencies emphasize the need
for consistency, but the diverse range of ancillary reagents available in the
market makes uniform compliance challenging.
Efforts to establish stringent quality control
measures and implement standardized protocols across reagent manufacturers are
necessary to address these concerns. Collaboration between industry leaders,
regulatory bodies, and research institutions can help create universally
accepted guidelines, ensuring reproducibility and reliability in scientific
applications.
Key Market Trends
Growing
Adoption of Automation and High-Throughput Technologies
The growing adoption of automation and high-throughput
technologies is significantly transforming the Global Ancillary Reagents Market
by enhancing efficiency, accuracy, and scalability in laboratory workflows.
Automation has become a critical component in clinical diagnostics, drug
discovery, and molecular biology applications, reducing manual errors and improving
reproducibility. High-throughput screening (HTS) and next-generation sequencing
(NGS) techniques require precise and reliable ancillary reagents to ensure
optimal performance. Laboratories and research institutions are investing in
robotic liquid handling systems, automated pipetting platforms, and integrated
data analysis software to streamline reagent preparation and application. These
technologies are accelerating research timelines, allowing for faster detection
of biomarkers, drug interactions, and disease mechanisms.
A study published in the Journal of Laboratory
Automation highlights that laboratory automation aims to manage increasing
workload demands, reduce errors, and enhance laboratory performance while
managing a limited labor force. The study emphasizes that improving laboratory
functions requires an orchestrated approach that integrates best practices in
lean work processes and IT support with skilled manpower. Informatics is
central to optimal laboratory automation usage, much as the electronic medical
record is now ubiquitous for effective management of a patient's medical
condition. Automation enabled by mechanics and information technology (IT)
allows laboratory staff who are IT-savvy to navigate and manage information
flow of the delivery, analytical, and archival systems. One effective way
to free up manpower time, especially with respect to result reporting, is to
enable auto-validation of standard test results. Through intelligent use of
auto-verification rules, about 80% of routine tests can be auto-validated and
released to the patients’ medical records. This approach not only improves
efficiency but also enhances patient safety by reducing the potential for human
error.
Biopharmaceutical companies and diagnostic
laboratories are integrating automated workflows to meet increasing demands for
large-scale testing and analysis. Automation enhances standardization in
experimental procedures, ensuring consistent reagent performance across
multiple assays. High-throughput technologies also support personalized
medicine by enabling rapid genomic and proteomic analyses. The shift toward
automated systems is driving demand for reagents that are compatible with
robotic handling and multiplexed assays. Reagent manufacturers are focusing on
developing high-purity, ready-to-use formulations that minimize variability and
enhance process efficiency. Regulatory agencies emphasize reproducibility and
accuracy in diagnostic and therapeutic applications, encouraging the adoption
of automation in reagent-based assays. As high-throughput technologies continue
to advance, the need for specialized ancillary reagents tailored to automated
systems will grow. These trends are reshaping laboratory operations, enabling
higher sample processing capacities while maintaining stringent quality control
standards. The integration of artificial intelligence (AI) and machine learning
in automated systems is further optimizing reagent utilization, reducing waste,
and improving experimental outcomes. With laboratories transitioning toward
automation-driven workflows, the demand for ancillary reagents designed for
high-throughput applications is expected to increase, shaping the future of the
market.
Increasing
Demand for GMP-Grade Reagents in Biopharmaceuticals
The increasing demand for Good Manufacturing Practice
(GMP)-grade reagents in biopharmaceuticals is shaping the growth of the Global
Ancillary Reagents Market. As biopharmaceutical companies focus on regulatory
compliance and product quality, the need for high-purity reagents that meet
stringent manufacturing standards has intensified. GMP-grade reagents are
essential in the development and production of biologics, vaccines, and cell
and gene therapies, ensuring consistency, safety, and efficacy in drug formulations.
With the expansion of biopharmaceutical pipelines and the rise in regulatory
scrutiny, manufacturers are prioritizing validated reagents that adhere to GMP
standards to meet global quality requirements.
The surge in monoclonal antibodies, recombinant
proteins, and cell-based therapies has heightened the necessity for reliable
ancillary reagents in upstream and downstream bioprocessing. GMP-grade reagents
minimize batch-to-batch variability and contamination risks, which are critical
factors in large-scale biopharmaceutical production. Regulatory agencies such
as the FDA and EMA emphasize the use of certified reagents in drug development,
compelling manufacturers to invest in compliant solutions. The shift toward
personalized medicine and advanced therapeutic modalities has further fueled
demand for reagents that support high-precision applications, including cell
culture, chromatography, and protein purification.
Biopharmaceutical firms are increasingly collaborating
with reagent suppliers to secure consistent access to GMP-compliant products
that align with evolving industry needs. Suppliers are expanding their
production capacities and enhancing quality control measures to meet the rising
demand for high-standard reagents. The trend is driving innovation in reagent
formulation, with a focus on extended stability, scalability, and compatibility
with automated workflows. As regulatory frameworks continue to evolve, the
emphasis on GMP-grade ancillary reagents will remain a key factor influencing
market dynamics, fostering growth opportunities for manufacturers catering to
the stringent requirements of biopharmaceutical development.
Segmental Insights
Product
Type Insights
Based
on the Product Type, Buffers emerged as the dominant segment in the Global
Ancillary Reagents Market in 2024. This is due to their indispensable role
in various laboratory applications, including clinical diagnostics, drug
discovery, molecular biology, and immunoassays. These reagents are essential
for maintaining pH stability, enzymatic activity, and overall reaction efficiency,
making them a fundamental component in biological and chemical research. The
increasing demand for highly specific and standardized buffer solutions in
diagnostic assays, next-generation sequencing (NGS), polymerase chain reaction
(PCR), and protein purification has significantly contributed to market growth.
The rising adoption of automated laboratory workflows and high-throughput
screening techniques has further boosted the need for pre-formulated,
high-quality buffer solutions that ensure reproducibility and accuracy. The
expansion of personalized medicine, biopharmaceutical research, and
point-of-care testing has also heightened the requirement for specialized
buffers tailored to specific applications.
End
User Insights
Based
on the End User, Pharmaceutical and Biotechnology Companies emerged as the
dominant segment in the
Global Ancillary Reagents Market in 2024. This dominance is due to
their extensive reliance on these reagents for drug discovery,
biopharmaceutical development, and quality control processes. The increasing
demand for biologics, biosimilars, and cell and gene therapies has
significantly driven the need for high-quality ancillary reagents that support
cell culture, molecular diagnostics, and analytical testing. These companies
require highly specialized reagents for preclinical and clinical research,
ensuring product consistency, safety, and regulatory compliance. The growing
investment in R&D activities, coupled with advancements in high-throughput
screening, next-generation sequencing (NGS), and protein expression studies,
has further propelled the demand for ancillary reagents. Regulatory agencies,
including the FDA and EMA, mandate stringent quality control protocols,
increasing the adoption of standardized reagents in drug development pipelines.
The expansion of biologics manufacturing facilities, rising clinical trial
volumes, and growing collaborations between pharmaceutical firms and research
institutes continue to reinforce the dominance of this segment in the market.
Download Free Sample Report
Regional Insights
North America emerged
as the dominant region in the Global Ancillary Reagents Market in 2024. This is due to
the presence of a well-established biopharmaceutical industry, advanced
research infrastructure, and strong regulatory framework supporting drug
discovery and development. The region is home to leading pharmaceutical and
biotechnology companies that require high-quality ancillary reagents for drug
formulation, clinical diagnostics, and molecular research. The increasing focus
on biologics, gene therapies, and personalized medicine has further fueled the
demand for specialized reagents that ensure precision and reproducibility in
research and manufacturing processes. The high investment in R&D
activities, expansion of biopharmaceutical manufacturing facilities, and the
presence of top-tier academic and research institutions contribute to market
growth. Regulatory bodies such as the FDA and Health Canada enforce stringent
quality and safety standards, driving the adoption of compliant ancillary
reagents for use in various applications, including cell culture, protein
analysis, and genetic studies. Additionally, the rising prevalence of chronic
diseases and infectious conditions has led to an increased need for diagnostic
reagents in clinical laboratories and hospitals. The region's strong funding
ecosystem, growing collaborations between research organizations and biotech
firms, and rapid technological advancements in life sciences further solidify
North America's market leadership.
Recent Developments
- In July 2024, EnPlusOne Biosciences
successfully synthesized the antisense strand of Leqvio (inclisiran), a siRNA
drug for hypercholesterolemia licensed by Alnylam and marketed by Novartis,
targeting millions of patients.
- In June 2024, Basecamp Research, in
partnership with the Ferruz Laboratory, launched ZymCTRL, an AI-powered tool
that generates enzyme sequences from scratch based on user-input enzyme
identification codes.
- In April 2024, UK-based Prozomix
partnered with Ginkgo Bioworks to enhance next-generation enzyme plate
production for API manufacturing. The collaboration combines Ginkgo’s
AI/ML-driven Enzyme Services with Prozomix’s enzyme libraries and manufacturing
expertise.
- In March 2024, StatLab Medical Products
acquired Poly Scientific R&D, a U.S.-based manufacturer of pathology
stains, tissue controls, reagents, and paraffin. This acquisition strengthens
StatLab’s manufacturing capabilities, enhances its anatomic pathology
consumables portfolio, and expands its market presence.
- In October 2023, Akron Biotechnology
announced the opening of its Sarasota, Florida, manufacturing facility to
produce plasmid DNA for the growing gene therapy and vaccine markets. The
facility enhances Akron’s capacity for ancillary material production,
supporting advanced therapies. Developed in partnership with Arcline Investment
Management, this is the company’s second manufacturing site in the US,
strengthening its position in the cell and gene therapy sector.
Key Market Players
- Thermo
Fisher Scientific Inc.
- Merck
KGaA
- Lonza
Group Ltd.
- Bio-Rad
Laboratories, Inc.
- Agilent
Technologies, Inc.
- PerkinElmer,
Inc.
- Qiagen
N.V.
- Promega
Corporation
- Sartorius
AG
- Miltenyi
Biotec B.V. & Co. KG
|
By Product Type
|
By Application
|
By End User
|
By Region
|
- Buffers
- Diluents
- Solvents
- Enzymes
- Stains & Dyes
- Others
|
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Molecular Biology
- Genomics & Proteomics
- Microbiology
- Others
|
- Hospitals & Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
- Research Institutions
- Contract Research Organizations
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Ancillary
Reagents Market has been segmented into the following categories, in addition
to the industry trends which have also been detailed below:
- Ancillary
Reagents Market,
By Product Type:
o
Buffers
o
Diluents
o
Solvents
o
Enzymes
o
Stains
& Dyes
o
Others
- Ancillary
Reagents Market,
By Application:
o
Clinical
Diagnostics
o
Drug
Discovery & Development
o
Immunology
o
Molecular
Biology
o
Genomics
& Proteomics
o
Microbiology
o
Others
- Ancillary
Reagents Market,
By End User:
o
Hospitals
& Diagnostic Laboratories
o
Pharmaceutical
and Biotechnology Companies
o
Research
Institutions
o
Contract
Research Organizations
o
Others
- Ancillary
Reagents Market, By Region:
o
North
America
§
United
States
§
Canada
§
Mexico
o
Europe
§
France
§
United
Kingdom
§
Italy
§
Germany
§
Spain
o
Asia-Pacific
§
China
§
India
§
Japan
§
Australia
§
South
Korea
o
South
America
§
Brazil
§
Argentina
§
Colombia
o
Middle
East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Ancillary Reagents Market.
Available Customizations:
Global Ancillary Reagents Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Global Ancillary Reagents Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]